Screening Elderly Adults in Rural Communities for Heart Failure Using an NT-proBNP-Guided Strategy in China (SEARCH-HF)
NCT07885488
Summary
Heart failure (HF) is common among older adults and is associated with substantial morbidity, mortality, and healthcare burden. Early stages of HF may be asymptomatic or present with nonspecific symptoms, making early detection challenging when screening relies primarily on clinical symptoms. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker that may help identify individuals with previously unrecognized cardiac dysfunction or HF. This study is a prospective, stratified, cluster-randomized controlled trial designed to evaluate an NT-proBNP-driven screening strategy for HF among adults aged 65 years or older in primary care settings. Participating clusters will be randomly assigned in a 1:1 ratio to either an NT-proBNP-guided HF screening strategy or symptom-based HF screening strategy. In the NT-proBNP-guided HF screening group, NT-proBNP will be measured in participants, and those with elevated NT-proBNP levels will be referred for further evaluation, including assessment of HF symptoms, echocardiography, to assess HF. In the symptom-based HF screening group, participants with typical symptoms suggestive of HF will be recommended for further evaluation with NT-proBNP testing and echocardiography for HF. The primary objective is to determine whether an NT-proBNP-guided screening strategy improves the detection rate of newly HF compared with conventional symptom-based HF screening. The study will also compare the HF positive rate and health economic outcomes between the two strategies, as well as adherence to guideline-directed medical therapy among patients with HF.
Eligibility
Inclusion Criteria: 1.Residents aged ≥65 years who are registered as permanent residents of Hushu Town, Jiangning District, Nanjing, China; 2. Have been residing in the local village for an extended period and are enrolled in routine health management services for older adults provided by the local primary healthcare institution; 3. Have normal cognitive function, are capable of independently understanding the study procedures and screening assessments, and voluntarily provide written informed consent. Exclusion Criteria: 1. An estimated life expectancy of less than 3 months based on a comprehensive assessment by a qualified clinician; 2. A confirmed diagnosis of schizophrenia, severe dementia, or other psychiatric or cognitive disorders that would preclude adequate cooperation with questionnaires, blood sampling, echocardiography, or other study-related screening procedures.
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07885488